... dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99(9):e162–e164. 29. Einsele H, Liebisch P, Langer C, et al. Velcade ... Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma ...
... autologous transplantation for multiple myeloma. Blood. 2005;106:35–39. 28. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + thalidomide ... Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell ...
... bortezomib in relapsed or refractory multiple myeloma . Br J Haematol 2004 ; 127 : 165–171 . 61. Richardson PG , Sonneveld P , Schuster MW , et al . Bortezomib or high- dose dexamethasone for ... Multiple Myeloma and Plasmacytoma 371.
... Superior Outcomes Associated with Complete Response : Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan - Prednisone Versus Melphalan - Prednisone . ASH ... Bortezomib, 32 Prognosis and Staging of Multiple Myeloma 635.
Abstract: In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with ...
... thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation ... velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57 ...
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders.
... dexamethasone ( RCD ) , is an effective and tolerated regimen for myeloma patients . Br J Haematol . 2007 ; 137 ( 3 ) : 268–269 . BORTEZOMIB Cyclophosphamide , 187.5 mg / m2 / day c.i.. REV / DEX LOW DOSE Lenalidomide , 25 mg p.o. days 1 ...
This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma.